FREEDOMS Phase III Multiple Sclerosis

FTY Shows Significant Benefits in Helping MS Patients Over One ...
PharmaLive.com (press release) - Newtown,PA,USA
... launched earlier in 2006 a Phase III clinical trials program called FREEDOMS (FTY720 Research Evaluating Effects of Daily Oral therapy in Multiple Sclerosis). ...

Fingolimod shows benefits in patients with relapsing multiple ...
Xagena.it - Italy
... Novartis launched a Phase III clinical trials program called FREEDOMS ( FTY720 Research Evaluating Effects of Daily Oral therapy in Multiple Sclerosis ). ...

---

FTY720

Phase II Data Showing Clinical Benefits Of Novel Once-Daily Oral ...
Medical News Today (press release) - UK
Clinical trial results published in the New England Journal of Medicine showed that FTY720 (fingolimod), a novel once-daily oral compound, demonstrated ...

---

fingolimod

Tough Targets
Corante - Boston,MA,USA
... lately. They've announced promising data for their odd immunosuppresive drug Fingolimod (FTY720) in multiple sclerosis therapy. ...